VESO

Pharmaceutical Manufacturing • Røddal, Akershus, Norway • 51-100 Employees

Company overview

Headquarters	Delitoppen 3, Vestby, Akershus 1540, NO
Phone number	+4722961100
Website	veso.no
NAICS	3254
SIC	873
Keywords	Animal Health, Regulatory, Pharmaceuticals, Research, GMP, Salmon, GCP, GLP, Vaccines, Aquaculture, Pharmacy, Feed, Breeding, Hatchery, Independence, Research Facility, Globalg.A.P, Fish Health, Cohabitation, Challenge Trials
Founded	1988
Employees	51-100
Socials

Key Contacts at VESO

Bjørn Skjævestad

Ceo

Nicollas Lehmann

Study Director / R&D Coordinator

Henry Bird

Study Director

Hilde Sloot Bjøru

Managing Director Veso Aqualab

Anne-Marja Jannok Joma

Study Director

Harshit Bajpai

Owner

VESO Email Formats

VESO uses 3 email formats. The most common is {2char} (e.g., {2char}@veso.no), used 93.1% of the time.

Format	Example	Percentage
{2char}	{2char}@veso.no	93.1%
{first initial}.{last name}	j.doe@veso.no	3.4%
{first name}.{last name}	john.doe@veso.no	3.4%

About VESO

VESO is a leading supplier and distributor of veterinary medicine in the Norwegian market, including aquaculture and terrestrial animals. The distribution of vaccines and pharmaceuticals takes place from the company's head office in Oslo; VESO Wholesaler and VESO Pharmacy. VESO Vikan and VESO Chile are aquatic research facilities that contract experimental challenge trials for the pharmaceutical-, feed- and breeding industries, research institutes and government agencies. Trials can be conducted according to GMP, GLP and GCP quality standards. The aim of the company is to contribute to improved fish and animal health by providing vaccines and pharmaceuticals, as well as services related to documentation of the efficacy and safety of the products. The company represents an independent research partner, and strives to maintain the highest scientific competence and integrity. VESO was established in 1988. The Norwegian state owns 34 percent of the shares in VESO. The other shares are owned by AquaNova Invest AS (61.3 per cent) and by 18 employees and former employees (4.7 per cent). VESO is a majority shareholder of Brynsløkken AS who produce antifouling products for the aquaculture industry.

VESO revenue & valuation

Annual revenue	$12,500,000
Revenue per employee	$241,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$40,000,000
Total funding	$120,000